Form 4: Humacyte Director Granted 80,000 Stock Options, Aligning Interests with Shareholders

Humacyte, Inc. Director Susan Richards Windham-Bannister was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Summary

• Susan Richards Windham-Bannister, a Director of Humacyte, Inc. (HUMA), was granted 80,000 stock options.
• The options have an exercise price of $2.41 per share.
• The transaction date for this grant was June 12, 2025.
• The options will expire on June 12, 2035.
• The vesting schedule for these options is as follows: the first 25% becomes exercisable on June 12, 2026, and thereafter, 1/48th of the option will become exercisable on the 12th of each month through June 12, 2029.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates an insider increasing their stake, which is generally viewed as a sign of confidence, though it's a routine compensation event.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The acquisition of options by an insider can signal confidence in the company's future prospects.

Future Outlook

The vesting schedule indicates that the director's ownership interest will gradually increase over the next four years, with full vesting expected by June 12, 2029, aligning their long-term incentives with the company's performance.

Industry Context

The grant of stock options is a common form of executive and director compensation in the biotechnology and healthcare sectors, aiming to incentivize long-term value creation and retain key talent.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across various industries, including biotechnology, to align director interests with shareholder value.
• The vesting schedule, typically over several years, is also a common mechanism to encourage long-term commitment and performance.

Related Party Transactions

• The transaction involves the grant of stock options from Humacyte, Inc. to Susan Richards Windham-Bannister, a director of the company, which constitutes a related-party transaction as it is between the company and an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Employees: No direct impact mentioned, but such compensation practices can influence overall company culture and incentive structures.

Next Steps

• The stock options will begin to vest on June 12, 2026, with subsequent monthly vesting until June 12, 2029.
• The director may choose to exercise the vested options at any time before their expiration on June 12, 2035.

Key Dates

Keywords

Humacyte, HUMA, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Corporate Governance